ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Haemodynamic instability | 24.03.02.006 | 0.000168% | | Not Available |
Gastrointestinal hypomotility | 07.02.02.005 | 0.000112% | | Not Available |
Catheter site erythema | 23.03.06.014; 12.07.02.003; 08.02.02.003 | 0.000246% | | Not Available |
Lymphatic disorder | 01.09.01.003 | - | - | Not Available |
Large intestinal haemorrhage | 24.07.02.026; 07.12.03.003 | 0.000168% | | |
Drug tolerance decreased | 08.06.01.024 | 0.000112% | | Not Available |
Perirectal abscess | 11.01.07.005; 07.19.04.001 | - | - | Not Available |
Musculoskeletal discomfort | 15.03.04.001 | - | - | Not Available |
Leukaemia cutis | 16.01.03.002; 01.10.03.002 | - | - | Not Available |
Inappropriate antidiuretic hormone secretion | 14.05.07.001; 05.03.03.001 | 0.000336% | | Not Available |
Febrile bone marrow aplasia | 08.05.02.005; 01.03.03.007 | 0.000504% | | Not Available |
Injection site swelling | 12.07.03.018; 08.02.03.017 | - | - | Not Available |
Cerebral haematoma | 17.08.01.014; 24.07.04.006 | 0.000112% | | Not Available |
Nodule | 08.03.05.002 | - | - | Not Available |
Klebsiella sepsis | 11.02.03.002 | - | - | Not Available |
Haemorrhoidal haemorrhage | 24.10.02.001; 07.15.03.002 | - | - | |
Infusion site reaction | 12.07.05.006; 08.02.05.005 | - | - | Not Available |
Haemorrhage | 24.07.01.002 | 0.002742% | | Not Available |
Haemorrhage urinary tract | 24.07.01.007; 20.02.03.005 | 0.000168% | | Not Available |
Faecaloma | 07.01.03.004 | 0.000504% | | Not Available |
Pulmonary mass | 22.02.07.004 | 0.000112% | | Not Available |
Intra-abdominal haematoma | 24.07.02.034; 07.12.02.005 | 0.000112% | | Not Available |
Pneumatosis intestinalis | 07.11.01.043 | 0.000280% | | Not Available |
Toxic skin eruption | 10.01.01.008; 12.03.01.073; 23.03.05.003 | 0.000168% | | Not Available |
Staphylococcal infection | 11.02.05.002 | - | - | Not Available |
Metabolic disorder | 14.11.01.001 | 0.000168% | | Not Available |
Lung neoplasm malignant | 22.08.01.001; 16.19.02.001 | 0.000504% | | Not Available |
Application site discolouration | 23.03.03.023; 12.07.01.030; 08.02.01.030 | 0.000112% | | Not Available |
Gastrointestinal toxicity | 12.03.01.019; 07.08.03.006 | 0.000694% | | Not Available |
Angiopathy | 24.03.02.007 | - | - | Not Available |